ViewRay to supply UK's GenesisCare with country's first MRIdian systems

October 31, 2018
by John R. Fischer, Staff Reporter
ViewRay Inc. is set to deliver the first of Great Britain’s MRIdian MR-guided radiotherapy systems as part of a new partnership between it and the cancer service provider, GenesisCare.

Deployed within the GenesisCare network, the first two systems will offer oncologists the ability to leverage soft-tissue imaging for the visualization of tumors, personalizing treatment with greater accuracy in the delivery of high-quality, image-guided, adaptive radiotherapy.

"Combining an MR scanner with a linear accelerator is the way of the future in radiotherapy, allowing us to see – for the first time – what's really happening inside the body during treatment,” Aldo Rolfo, executive manager for GenesisCare Europe, said in a statement. “This will enable our clinicians to offer truly personalized radiotherapy by adapting treatment in real time, to better target tumors and minimize side effects for patients."

The system integrates MR technology, radiation delivery, and proprietary software to locate, target and track the position and shape of tumors while radiation is delivered, with its application of MR guidance reducing uncertainty involved in treatment.

Installation of the solution follows an earlier installation and commissioning this year at the University Clinic Heidelberg in Germany, as well as the awarding of a tender for installation at Centre Georges-François Leclerc in France.

In addition, the system is now equipped with MR pulse sequencing, higher image resolution, improvement in MR noise-to-signal ratio; and the integration of diffusion-weighted imaging, features showcased earlier this year at ESTRO 2018 in Barcelona, Spain.

Comprising more than 2,500 healthcare professionals and supporting staff members, GenesisCare delivers radiotherapy to more than 160,000 patients annually at 12 centers throughout the U.K., 21 in Spain and 30 in Australia.

"The reach of the GenesisCare network is vast and their investment in MRIdian is a testament to its industry-leading innovation for on-table adaptive therapy,” Scott Drake, president and CEO of ViewRay, said in a statement. “We are proud to be revolutionizing the field of radiation oncology."

News of MRIdian’s arrival has already been met with warm welcomes and cheers from Britain’s radiology community. #ViewRay MRIdian will be the focus of a new network of experienced #SABR clinicians and treatment teams, dedicated to bringing top flight IGRT and clinical trials to more patients,” tweeted cancer consultant specialist and oncologist Dr. James Good of Queen Elizabeth Hospital in Birmingham. “Delighted to be part of this effort…”

The system was cleared by the FDA in 2012 and CE marked in 2014.